2023
Randomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia
Surti T, Ranganathan M, Johannesen J, Gueorguieva R, Deaso E, Kenney J, Krystal J, D'Souza D. Randomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia. Schizophrenia Research 2023, 256: 36-43. PMID: 37141764, PMCID: PMC10257994, DOI: 10.1016/j.schres.2023.04.010.Peer-Reviewed Original ResearchConceptsGlycine transporter 1Cytochrome P450 2D6 extensive metabolizersGlyT1 inhibitorsWeeks of washoutWeeks of CTMedication adherenceReceptor hypofunctionImpaired neuroplasticityPharmacodynamic variabilityNMDAR functionExtensive metabolizersTreatment periodPsychotic symptomsStable outpatientsCognitive impairmentGlyT1 occupancyTransporter 1CTNeuroplasticityCognitive training strategiesSchizophreniaComputerized CTCognitive performanceAugmentation studiesGreater improvement
2012
Enhancing Prolonged Exposure Therapy for Posttraumatic Stress Disorder with D-Cycloserine: Further Support for Treatments That Promote Experience-Dependent Neuroplasticity
Krystal JH. Enhancing Prolonged Exposure Therapy for Posttraumatic Stress Disorder with D-Cycloserine: Further Support for Treatments That Promote Experience-Dependent Neuroplasticity. Biological Psychiatry 2012, 71: 932-934. PMID: 22579302, DOI: 10.1016/j.biopsych.2012.03.031.Peer-Reviewed Original Research
2009
Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia
Krystal JH, Tolin DF, Sanacora G, Castner SA, Williams GV, Aikins DE, Hoffman RE, D'Souza DC. Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia. Drug Discovery Today 2009, 14: 690-697. PMID: 19460458, PMCID: PMC2898127, DOI: 10.1016/j.drudis.2009.05.002.Peer-Reviewed Original ResearchConceptsPsychiatric disordersSymptomatic reliefMood disordersAnxiety disordersNeuroplasticity deficitsCurrent pharmacotherapyUnderlying abnormalityCurrent treatmentPsychiatric treatmentNeuroplasticityDisordersPharmacotherapyTreatmentExciting new findingsSchizophreniaReliefAbnormalitiesNeurodevelopmentNew findingsPrevention
2007
Neuroplasticity as a Target for the Pharmacotherapy of Psychiatric Disorders: New Opportunities for Synergy with Psychotherapy
Krystal JH. Neuroplasticity as a Target for the Pharmacotherapy of Psychiatric Disorders: New Opportunities for Synergy with Psychotherapy. Biological Psychiatry 2007, 62: 833-834. PMID: 17916459, DOI: 10.1016/j.biopsych.2007.08.017.Peer-Reviewed Original Research